dr. gottlieb. then i want to go to dr. collins. the action plan which strives to encourage more innovation and competition. i believe such action is critical and necessary. realize thel better importance of bio similars. years have passed. only three bio similars are marketed despite the fda having approved 11 of them. you noted competition is anemic. the high costware of prescription drugs including biologics continues to be a barrier for many patients. you revealed a recent analysis has found in all fda approved by a similar's were available to american consumers, savings could be realized. could you discuss further fda's analysis and the savings potential bio similars could offer? >> i appreciate the question. we going to be publishing full results. we look to the experience in the european market, where we saw product introductions and extrapolated that to what could have happened in the u.s. market if the same product have been introduced in the u.s.. we effectively took the competitive landscape from europe, made some correct

dr. scott gottlieb has been talking to us about for years and years and now he's in a position to actuallyme policy decisions. joining us now, fda commissioner dr. scott gottlieb good interview, scott. it was like required reading over the weekend you got a lot off your chest there too and it's -- you know what i decided from reading it things are really nuanced and you need -- it's not a sound bite that tells us how to deal with prescription drug prices, chronic illnesses, opioid addiction. these are all things we need to approach carefully and methodically to try to make some headway on. >> it's a complicated environment. i think it's also an environment where we're seeing a lot of opportunity. there's tremendous progress being made we're still doing a lot to try to address issues of drug pricing and competition. we'll be announcing some new policies coming up i think there's a lot of unfinished business that we can attack. >> can you be more clear about what some of these initiatives might be in terms of competition? >> sure. one of the places that we focused a lot of attention is on co

dr. scott gottlieb, talking about agency priorities before the senate health committee, at 10:00 eastern, also on c-span. sadness to say, judge kavanaugh, you don't belong in this building as a justice. beyond the extraordinary career and extraordinary intellect and extraordinary record of this judge you find a character and a humility that leftith strength me just profoundly impressed. >> the point i am making here is that 35 month

dr. scott gottlieb, commissioner of the food and drug administration. the committee will stand adjourned. [indiscernible] >> into a reasonably biomedical , the way theye , there's a lot going on in biomedical research. they are intentionally trying to gain expertise in the biomedical community. >> the penalty for can be losing yourm ability to have your grant, to ever getting grants and to criminal activity. all pending on the severity. technology in a particular area and potential mischief because of the intellectual property. you mentioned the risk of increasing them. be that there is more funding been put into this by foreign governments. they have found it an attractive way to go there --. >> thank you. if you missed any live coverage of this hearing, it will be available to view online shortly at our website, c-span.org. we have more like programming coming up, a pound discussion on the current climate in afghanistan. tonight it's a hearing on the cancer shot that's implemented under the 21st century cures at. you can see that tonight starting at e

dr. scott gottlieb, commissioner of the food and drug administration. the committee will stand adjourned. >> could you give us -- -- abe a wind oo gnat how inaudible] >> that was interesting. that intervaw was done last november prepted as a showtime ecial where the interviewers is somebody who doesn't know a lot about medical research but gives you a chance to talk about the exciting things to happen. a faw minutes gnat it it was pretty clear this was not the usual circumstance. but i decided to play it safe. and you saw the results. you saw three minutes of about an hour of a very interesting conversation. >> did you consider cutting hour short? >> maybe a public health message that could get wrapped in and there was a bit about needle sharing. so o there you go. back the real business. in terms of the undue foreign influences there has been a controversy at duke. is there a specific nih incident? >> there have been specific bac instances some of which we are still exploring. we have sent letters now to a faw institutions saying we are concerned about

dr. scott gottlieb, commissioner of the food and drug administration. thank you for being here. the committee will stand adjourned. [indiscernible] >> the interviewer is someone doesn't know a lot about medical a few minutes into it, it was clear that this was not the usual circumstances. i decided to just play it safe. it's a very interesting conversation. >> did you consider cutting that our short? >> i certainly did. maybe there's a public health message that could be wrapped in here. and there was. things . reporter: i know there has been a controversy at duke, regarding a specific nih incident, any catalyst about that discussion? there has been a specific incidents that we are exploring cover we sent a letter to the institution saying that we are concerned about the investigator in your faculty. reporter: more specifically. >> yes, we have evidence of somebody who has an nih grant and is getting a lot of money from a foreign government, that should have been included in the grant application, and we're asking them to look into it. reporter: how short is that list? >> it is